| 产品描述： | CaCC阻滞剂和Cl- / HCO3-交换抑制剂;CaCC blocker and Cl-/HCO3- exchange inhibitor;; |
| 靶点： |
IC50: Ca2+-activated Cl- channel (CaCC) |
| 体内研究： |
Talniflumate (oral chow; 0.4 mg/g; 21 days) significantly increases CF mouse survival from 26 to 77%. It does not alter crypt goblet cell numbers or change intestinal expression of mCLCA3 but tends to decrease crypt mucoid impaction. |
| 参考文献： |
1. Hyun-Ji Kim, et al. Pharmacokinetics of talniflumate, a prodrug of niflumic acid, following oral administration to man. Archives of Pharmacal Research volume 19, Article number: 297 (1996)2. Mollereau, et al. Agonist and Antagonist Activities on Human NPFF(2) Receptors of the NPY Ligands GR231118 and BIBP3226. Br J Pharmacol.2001 May;133(1):1-4. |
| 保存条件： |
-80℃（运输条件：冰袋低温运输） |
| 配置溶液浓度参考： |
|
1mg |
5mg |
10mg |
| 1 mM |
2.413 ml |
12.067 ml |
24.135 ml |
| 5 mM |
0.483 ml |
2.413 ml |
4.827 ml |
| 10 mM |
0.241 ml |
1.207 ml |
2.413 ml |
| 50 mM |
0.048 ml |
0.241 ml |
0.483 ml |
|
| 注意： |
部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京